Streptococcus pneumoniae News and Research

RSS

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations of developing pneumococcal infections. According to the WHO, the bacterium kills up to one million children under the age of five years each year worldwide. It accounts for many Bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, Pneumonia, Meningitis and Otitis media in young children.

Streptococcus biofilms persist on objects, surfaces in daycare center for longer periods after cleaning

Numerous scientific studies have concluded that two common bacteria that cause colds, ear infections, strep throat and more serious infections cannot live for long outside the human body.

27 Dec 2013

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

23 Dec 2013

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

Children hospitalized for pneumonia have similar outcomes, including length of stay and costs, regardless of whether they are treated with "big gun" antibiotics such as ceftriaxone or cefotaxime or more narrowly focused antibiotics such as ampicillin or penicillin, according to a Vanderbilt study published in Pediatrics.

10 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

Novel urinary antigen test boosts S. pneumoniae CAP detection

Research published in the European Respiratory Journal shows that addition of a serotype-specific urinary antigen detection test to existing diagnostic methods can increase the detection of Streptococcus pneumoniae community-acquired pneumonia by over a third.

25 Nov 2013

Researchers find zinc starves bacteria by preventing its uptake of essential metal

Australian researchers have found that zinc can 'starve' one of the world's most deadly bacteria by preventing its uptake of an essential metal.

11 Nov 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Urinary pneumococcal antigen testing ‘useful in children’

Urinary antigen testing is effective in detecting invasive pneumococcal pneumonia in children, say the authors of a UK-based case–control study.

23 Sep 2013

Research shows how mammalian and bacterial kingdoms interact

The bacteria Streptococcus pneumoniae harmlessly colonizes the mucous linings of throats and noses in most people, only becoming virulent when they leave those comfortable surroundings and enter the middle ears, lungs or bloodstream. Now, in research published in July in mBio, University at Buffalo researchers reveal how that happens.

8 Aug 2013

MAPS method could speed development of new vaccines for serious pathogens

A new method of vaccine design, called the Multiple Antigen Presentation System, may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination.

1 Aug 2013

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

Common sugar molecule promising target for development of broad-spectrum vaccine

Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges-one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens.

28 May 2013

Research: Protein complex in human breast milk can help reverse antibiotic resistance

A protein complex found in human breast milk can help reverse the antibiotic resistance of bacterial species that cause dangerous pneumonia and staph infections, according to new University at Buffalo research.

3 May 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

30 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

29 Apr 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

ADMA Biologics initiates enrollment in RI-002 Phase III study for PIDD

ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that the first patient enrolled in the pivotal Phase III clinical study of its RI-002 has been dosed.

7 Mar 2013

Nursing home patients with pneumonia may need viral screening

Viral testing should be carried out among all older individuals who have been admitted to hospital for nursing home-acquired pneumonia, recommend researchers.

5 Mar 2013

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).

5 Mar 2013

Streptococcus pneumoniae News and Research

Further Reading

Streptococcus biofilms persist on objects, surfaces in daycare center for longer periods after cleaning

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Novel urinary antigen test boosts S. pneumoniae CAP detection

Researchers find zinc starves bacteria by preventing its uptake of essential metal

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Urinary pneumococcal antigen testing ‘useful in children’

Research shows how mammalian and bacterial kingdoms interact

MAPS method could speed development of new vaccines for serious pathogens

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Common sugar molecule promising target for development of broad-spectrum vaccine

Research: Protein complex in human breast milk can help reverse antibiotic resistance

Specific inflammatory pattern found in patients with pneumonia and COPD

Specific inflammatory pattern found in patients with pneumonia and COPD

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

ADMA Biologics initiates enrollment in RI-002 Phase III study for PIDD

Nursing home patients with pneumonia may need viral screening

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News